Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practice

The JAVELIN Bladder 100 phase III trial led to the incorporation of avelumab first-line (1L) maintenance treatment into international guidelines as a standard of care for patients with advanced urothelial carcinoma (UC) without progression after 1L platinum-based chemotherapy. JAVELIN Bladder 100 sh...

Descripción completa

Detalles Bibliográficos
Autores principales: Grivas, P., Grande, E., Davis, I.D., Moon, H.H., Grimm, M.-O., Gupta, S., Barthélémy, P., Thibault, C., Guenther, S., Hanson, S., Sternberg, C.N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10685024/
https://www.ncbi.nlm.nih.gov/pubmed/37976999
http://dx.doi.org/10.1016/j.esmoop.2023.102050

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10685024/
https://www.ncbi.nlm.nih.gov/pubmed/37976999
http://dx.doi.org/10.1016/j.esmoop.2023.102050

Ejemplares similares